Does BMRN pay a dividend?

The cached stock data on this page does not show a positive dividend yield for BMRN. Dividend status can change, so verify the latest company filings before relying on income assumptions.

What does BMRN stock do?

Commercial-stage rare disease biopharmaceutical company developing and selling precision enzyme replacement therapies and genetic medicines globally.

What is BMRN stock's price target?

This cached page does not contain a precise model fair value for BMRN.

The TradeMates model verdict for BMRN is HOLD with an investment score of 61/100. Treat this as a model signal to review, not a personal buy recommendation.

Is BMRN a good dividend stock?

BMRN is not presented as a dividend idea on this cached TradeMates page because no positive dividend yield is available in the cached data.

BMRN (BMRN) Stock Analysis

Q: Is BMRN stock a good investment?

The cached TradeMates AI model rates BMRN as HOLD with an investment score of 61/100. The model score of 61/100 falls in the HOLD range. The central thesis and factor breakdown explain the assessment. This is algorithmic model output, not personal investment advice.

Verdict: HOLD

Voxzogo's achondroplasia expansion and $725M FCF balance pipeline setbacks and past EPS misses, supporting moderate upside.

Investment score: 61/100

The model score of 61/100 falls in the HOLD range. The central thesis and factor breakdown explain the assessment.

Peers

NBIX
EXEL
SMMT
BBIO
HALO

Peer	P/E	P/B	P/S	EV/EBITDA	ROIC %	Net margin %
NBIX	21.41	4.13	4.50	16.61	—	0.21
EXEL	17.64	7.89	5.99	13.91	—	0.35
SMMT	-15.90	22.00	0.00	-16.14	—	0.00
BBIO	-19.20	-5.35	19.46	-25.35	—	-1.01
HALO	30.83	88.67	7.74	20.81	—	0.25

View the full interactive analysis